Quick Answer
Corvus Pharmaceuticals, Inc. reported Operating Income of -$42.97 million for fiscal year 2025.
Corvus Pharmaceuticals, Inc. Operating Income — Annual History
| Fiscal Year | Operating Income | YoY Change |
|---|---|---|
| 2025 | -$42.97M | -56.0% |
| 2024 | -$27.55M | -17.7% |
| 2023 | -$23.41M | +28.1% |
| 2022 | -$32.56M | +15.7% |
| 2021 | -$38.63M | +11.7% |
| 2020 | -$43.76M | +10.4% |
| 2019 | -$48.85M | +0.7% |
| 2018 | -$49.22M | +12.9% |
| 2017 | -$56.52M | -52.9% |
| 2016 | -$36.98M | -168.5% |
| 2015 | -$13.77M | -8452.8% |
| 2014 | -$161.0K | — |
Quarterly Operating Income
| Quarter Ending | Operating Income | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | -$10.57M | -45.7% | -3.0% |
| June 30, 2025 | -$10.26M | -72.9% | -3.4% |
| March 31, 2025 | -$9.92M | -58.7% | -36.8% |
| September 30, 2024 | -$7.25M | -30.5% | -22.2% |
| June 30, 2024 | -$5.93M | -5.6% | +5.1% |
| March 31, 2024 | -$6.25M | +4.9% | -12.5% |
| September 30, 2023 | -$5.56M | +55.4% | +1.1% |
| June 30, 2023 | -$5.62M | +19.8% | +14.5% |
- Corvus Pharmaceuticals, Inc. showed a decrease of -56.0% in Operating Income compared to the prior fiscal year.
- Over the 2014–2025 period, Corvus Pharmaceuticals, Inc.’s operating income has declined by 26590.1% (from -$161.0 thousand to -$42.97 million).
- The most recent figure is from Corvus Pharmaceuticals, Inc.’s fiscal year 2025 report (Form 10-K), filed with the SEC on March 12, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: